Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.
Choose from the criteria below to find an activity that fits you best.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349.
Upon completion of this activity, the reader will be able to:
Dennis J. Cada, PharmD, FASHP, FASCP (Editor)
Executive Editor, The Formulary
Facts & Comparisons
Danial E. Baker, PharmD, FASHP, FASCP
Director, Drug Information Center
Professor of Pharmacy Practice, College of Pharmacy
Washington State University
Drug Information Intern, College of Pharmacy
Washington State University
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Dr. Cada, Dr. Baker, and Dr. Leonard have reported that they have no significant financial or commercial relationships to disclose.
Please note: The information and views presented in this CE activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications. Use of drugs and/or devices outside of labeling should be considered experimental. Participants are advised to consult and verify manufacturer product information, the professional literature and use his/her professional judgment in applying the presented information in patient care activities.
This CE activity is jointly provided by ProCE, Inc. and Hospital Pharmacy. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-15-272-H01-P has been assigned to this knowledge-based home-study CE activity (initial release date 12-1-15). This CE activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.
Release Date: 12-1-2015
Expiration Date: 12-1-2017
This activity is self-funded by Hospital Pharmacy.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.